Xencor Inc. (XNCR) Given a $32.00 Price Target by Canaccord Genuity Analysts
Canaccord Genuity set a $32.00 target price on Xencor Inc. (NASDAQ:XNCR) in a research report report published on Monday morning. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.
Other equities analysts have also recently issued research reports about the company. TheStreet cut Xencor from a hold rating to a sell rating in a report on Tuesday, November 8th. Wedbush reissued an outperform rating and issued a $27.00 price objective on shares of Xencor in a report on Monday, September 12th. Leerink Swann reissued a buy rating and issued a $26.00 price objective on shares of Xencor in a report on Thursday, November 3rd. Zacks Investment Research cut Xencor from a buy rating to a hold rating in a report on Wednesday, August 31st. Finally, Piper Jaffray Cos. began coverage on Xencor in a report on Tuesday, October 4th. They issued an overweight rating and a $35.00 price objective for the company. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company. The company currently has an average rating of Buy and an average target price of $27.14.
Xencor (NASDAQ:XNCR) traded up 2.23% during trading on Monday, hitting $26.58. The stock had a trading volume of 158,433 shares. The stock has a 50 day moving average price of $22.59 and a 200-day moving average price of $19.88. Xencor has a 12 month low of $9.89 and a 12 month high of $28.09. The stock has a market cap of $1.09 billion, a price-to-earnings ratio of 27.23 and a beta of 2.20.
WARNING: This piece of content was first reported by Financial Market News and is the propert of of Financial Market News. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States and international copyright and trademark law. The original version of this piece of content can be viewed at http://www.financial-market-news.com/xencor-inc-xncr-given-a-32-00-price-target-by-canaccord-genuity-analysts/1208871/.
In other Xencor news, major shareholder John S. Stafford III sold 40,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 27th. The stock was sold at an average price of $25.72, for a total transaction of $1,028,800.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Edgardo Baracchini, Jr. sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, September 2nd. The stock was sold at an average price of $21.06, for a total value of $210,600.00. Following the sale, the insider now owns 10,000 shares of the company’s stock, valued at $210,600. The disclosure for this sale can be found here. 4.03% of the stock is owned by corporate insiders.
Large investors have recently bought and sold shares of the company. Acrospire Investment Management LLC raised its stake in Xencor by 8.5% in the second quarter. Acrospire Investment Management LLC now owns 6,347 shares of the biopharmaceutical company’s stock valued at $121,000 after buying an additional 495 shares during the period. DIAM Co. Ltd. purchased a new stake in Xencor during the third quarter valued at approximately $154,000. BlackRock Inc. raised its stake in Xencor by 363.5% in the second quarter. BlackRock Inc. now owns 11,350 shares of the biopharmaceutical company’s stock valued at $215,000 after buying an additional 8,901 shares during the period. Capital Fund Management S.A. purchased a new stake in Xencor during the third quarter valued at approximately $220,000. Finally, Zacks Investment Management purchased a new stake in Xencor during the third quarter valued at approximately $249,000. Institutional investors own 70.71% of the company’s stock.
Xencor Company Profile
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. Its segment is related to the development of pharmaceutical products. It uses its XmAb technology platform to create antibody product candidates designed to treat autoimmune and allergic diseases, cancer and other conditions.
Receive News & Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related companies with MarketBeat.com's FREE daily email newsletter.